Related Experiment Video

Updated: Jun 29, 2025

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

9.5K

A big step for MYC-targeted therapies

Danielle F Atibalentja1, Anja Deutzmann1, Dean W Felsher2

  • 1Division of Oncology, Department of Medicine, Stanford University, Stanford, CA 94305, USA.

Trends in Cancer
|April 5, 2024
PubMed

Insights

Researchers are exploring OMO-103, a novel therapeutic targeting the MYC proto-oncogene, a key driver in many cancers. Early clinical trials show promise for this much-needed cancer drug.

Area of Science:

  • Oncology
  • Molecular Biology
  • Clinical Pharmacology

Background:

  • The MYC proto-oncogene is a crucial transcriptional regulator frequently altered in human cancers.
  • Developing effective MYC-targeted therapies remains a significant challenge in oncology drug development.
  • Targeting MYC is considered a 'holy grail' due to its central role in cancer progression.

Purpose of the Study:

  • To review the Phase 1 clinical trial of OMO-103, a novel therapeutic agent.
  • To assess the safety and tolerability of OMO-103 in patients with solid malignancies.
  • To provide an overview of early clinical findings for a potential MYC-targeted drug.

Main Methods:

  • Phase 1 clinical trial design.
  • Recruitment of patients with solid malignancies.
  • Administration and monitoring of OMO-103 dosage and patient response.

Main Results:

  • The report by Garralda et al. details the outcomes of the Phase 1 trial.
  • Initial safety and tolerability data for OMO-103 were presented.
  • Early efficacy signals may be emerging, warranting further investigation.

Conclusions:

  • OMO-103 represents a potential new therapeutic strategy for cancers driven by MYC dysregulation.
  • The Phase 1 trial provides a foundation for future clinical development of OMO-103.
  • Further research is needed to confirm the efficacy and expand the use of MYC-targeted therapies.
Keywords:
MYCOMO-103Omomyccancerimmunotherapyoncogene addictiontumor

More Related Videos

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells09:37

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells

Published on: August 25, 2021

1.8K
Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.3K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
523
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.6K